Skip to main content

Advertisement

SpringerLink
Log in

Itraconazole may increase the risk of early-onset bortezomib-induced peripheral neuropathy

  • Original Article
  • Published:
International Journal of Hematology Aims and scope Submit manuscript

Abstract

Bortezomib (BOR) is an effective drug for the treatment of multiple myeloma and BOR-induced peripheral neuropathy (BIPN) is a major adverse event. BIPN tends to occur after two or three cycles of treatment (late-onset BIPN), but may occur during the first treatment cycle (early-onset BIPN). BIPN severity was retrospectively assessed and graded in 48 patients with relapsed or refractory multiple myeloma treated with BOR for the first time between June 2007 and February 2011 at Keio University Hospital. PN grade 2 or higher occurring within the first cycle of BOR was defined as early-onset severe BIPN. Early-onset severe BIPN occurred in 13 patients. Concomitant use of itraconazole [ITCZ: odds ratio (OR) 29.14 (3.02–281.56), p = 0.004] and a proton pump inhibitor [OR 9.00 (1.05–77.1), p = 0.04] were identified by univariate analysis, as risk factors for developing early-onset severe BIPN. Based on multivariate analysis, concomitant use of ITCZ was the only significant risk factor for developing early-onset severe BIPN [OR 19.00 (1.89–190.96), p = 0.01]. Concomitant use of ITCZ with BOR significantly increased the incidence of early-onset severe BIPN in our study population, suggesting that administration of ITCZ in patients receiving BOR should be avoided.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. San Miguel J, Bladé J, Boccadoro M, Cavenagh J, Glasmacher A, Jagannath S, et al. A practical update on the use of bortezomib in the management of multiple myeloma. Oncologist. 2006;11:51–61.

    Article  PubMed  CAS  Google Scholar 

  2. Cavo M, Rajkumar SV, Palumbo A, Moreau P, Orlowski R, Bladé J, International Myeloma Working Group. International Myeloma Working Group consensus approach to the treatment of multiple myeloma patients who are candidates for autologous stem cell transplantation. Blood. 2011;117:6063–73.

    Article  PubMed  CAS  Google Scholar 

  3. Richardson PG, Barlogie B, Berenson J, Singhal S, Jagannath S, Irwin D, et al. A phase 2 study of bortezomib in relapsed, refractory myeloma. N Engl J Med. 2003;348:2609–17.

    Article  PubMed  CAS  Google Scholar 

  4. Jagannath S, Barlogie B, Berenson J, Siegel D, Irwin D, Richardson PG, et al. A phase 2 study of two doses of bortezoib in relapsed or refractory myeloma. Br J Haematol. 2004;127:165–72.

    Article  PubMed  CAS  Google Scholar 

  5. Badros A, Goloubeva O, Dalal JS, Can I, Thompson J, Rapoport AP, et al. Neurotoxicity of bortezomib therapy in multiple myeloma: a single-center experience and review of the literature. Cancer. 2007;110:1042–9.

    Article  PubMed  CAS  Google Scholar 

  6. Corso A, Mangiacavalli S, Varettoni M, Pascutto C, Zappasodi P, Lazzarino M. Bortezomib-induced peripheral neuropathy in multiple myeloma: a comparison between previously treated and untreated patients. Leuk Res. 2010;34:471–4.

    Article  PubMed  CAS  Google Scholar 

  7. Richardson PG, Briemberg H, Jagannath S, Wen PY, Barlogie B, Berenson J, et al. Frequency, characteristics, and reversibility of peripheral neuropathy during treatment of advanced multiple myeloma with bortezomib. J Clin Oncol. 2006;24:3113–20.

    Article  PubMed  CAS  Google Scholar 

  8. Richardson PG, Sonneveld P, Schuster MW, Stadtmauer EA, Facon T, Harousseau JL, et al. Reversibility of symptomatic peripheral neuropathy with bortezomib in the phase III APEX trial in relapsed multiple myeloma: impact of a dose-modification guideline. Br J Haematol. 2009;144:895–903.

    Article  PubMed  CAS  Google Scholar 

  9. Dimopoulos MA, Mateos MV, Richardson PG, Schlag R, Khuageva NK, Shpilberg O, et al. Risk factors for, and reversibility of, peripheral neuropathy associated with bortezomib-melphalan-prednisone in newly diagnosed patients with multiple myeloma: subanalysis of the phase 3 VISTA study. Eur J Haematol. 2011;86:23–31.

    Article  PubMed  CAS  Google Scholar 

  10. Bang SM, Lee JH, Yoon SS, Park S, Min CK, Kim CC, Korean Multiple Myeloma Working Party, et al. A multicenter retrospective analysis of adverse events in Korean patients using bortezomib for multiple myeloma. Int J Hematol. 2006;83:309–13.

    Article  PubMed  CAS  Google Scholar 

  11. El-Cheikh J, Stoppa AM, Bouabdallah R, de Lavallade H, Coso D, de Collela JM, et al. Features and risk factors of peripheral neuropathy during treatment with bortezomib for advabced multiple myeloma. Clin Lymphoma Myeloma. 2008;8:146–52.

    Article  PubMed  CAS  Google Scholar 

  12. Iwamoto T, Ishibashi M, Fujieda A, Masuya M, Katayama N, Okuda M. Drug interaction between itraconazole and bortezomib: exacerbation of peripheral neuropathy and thrombocytopenia induced by bortezomib. Pharmacotherapy. 2010;30:661–5.

    Article  PubMed  CAS  Google Scholar 

  13. Bringhen S, Larocca A, Rossi D, Cavalli M, Genuardi M, Ria R, et al. Efficacy and safety of once-weekly bortezomib in multiple myeloma patients. Blood. 2010;116:4745–53.

    Article  PubMed  CAS  Google Scholar 

  14. Durie BG, Harousseau JL, Miguel JS, Bladé J, Barlogie B, Anderson K, International Myeloma Working Group, et al. International uniform response criteria for multiple myeloma. Leukemia. 2006;20:1467–73.

    Article  PubMed  CAS  Google Scholar 

  15. Pekol T, Daniels JS, Labutti J, Parsons I, Nix D, Baronas E, et al. Human metabolism of the proteasome inhibitor bortezomib: identification of circulating metabolites. Drug Metab Dispos. 2005;33:771–7.

    Article  PubMed  CAS  Google Scholar 

  16. Uttamsingh V, Lu C, Miwa G, Gan LS. Relative contributions of the five major human cytochromes P450, 1A2, 2C9, 2C19, 2D6, and 3A4, to the hepatic metabolism of the proteasome inhibitor bortezomib. Drug Metab Dispos. 2005;33:1723–8.

    Article  PubMed  CAS  Google Scholar 

  17. Zanger UM, Turpeinen M, Klein K, Schwab M. Functional pharmacogenetics/genomics of human cytochromes P450 involved in drug biotransformation. Anal Bioanal Chem. 2008;392:1093–108.

    Article  PubMed  CAS  Google Scholar 

  18. Broyl A, Corthals SL, Jongen JL, van der Holt B, Kuiper R, de Knegt Y, et al. Mechanisms of peripheral neuropathy associated with bortezomib and vincristine in patients with newly diagnosed multiple myeloma: a prospective analysis of data from the HOVON-65/GMMG-HD4 trial. Lancet Oncol. 2010;11:1057–65.

    Article  PubMed  CAS  Google Scholar 

  19. Vangsted AJ, Søeby K, Klausen TW, Abildgaard N, Andersen NF, Gimsing P, et al. No influence of the polymorphisms CYP2C19 and CYP2D6 on the efficacy of cyclophosphamide, thalidomide, and bortezomib in patients with Multiple Myeloma. BMC Cancer. 2010;10:404–11.

    Article  PubMed  Google Scholar 

  20. Hellmann A, Rule S, Walewski J, Shpilberg O, Feng H, van de Velde H, et al. Effect of cytochrome P450 3A4 inducers on the pharmacokinetic, pharmacodynamic and safety profiles of bortezomib in patients with multiple myeloma or non-Hodgkin’s lymphoma. Clin Pharmacokinet. 2011;50:781–91.

    Article  PubMed  CAS  Google Scholar 

  21. Venkatakrishnan K, Rader M, Ramanathan RK, Ramalingam S, Chen E, Riordan W, et al. Effect of the CYP3A inhibitor ketoconazole on the pharmacokinetics and pharmacodynamics of bortezomib in patients with advanced solid tumors: a prospective, multicenter, open-label, randomized, two-way crossover drug–drug interaction study. Clin Ther. 2009;31(Pt 2):2444–58.

    Article  PubMed  CAS  Google Scholar 

  22. Quinn DI, Nemunaitis J, Fuloria J, Britten CD, Gabrail N, Yee L, et al. Effect of the cytochrome P450 2C19 inhibitor omeprazole on the pharmacokinetics and safety profile of bortezomib in patients with advanced solid tumours, non-Hodgkin’s lymphoma or multiple myeloma. Clin Pharmacokinet. 2009;48:199–209.

    Article  PubMed  CAS  Google Scholar 

  23. Igarashi N, Chou T, Hirose T, Imai Y, Ishiguro T. Bortezomib nd dexamethasone for Japanese patients with relapsed and refractory multiple myeloma: a single center experience. Int J Hematol. 2010;92:518–23.

    Article  PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Division of Hematology, Department of Medicine, Keio University School of Medicine, 35 Shinano-machi, Shinjuku-ku, Tokyo, 160-8582, Japan

    Norisato Hashimoto, Kenji Yokoyama, Ken Sadahira, Tomoki Ueda, Yuiko Tsukada & Shinichiro Okamoto

Authors
  1. Norisato Hashimoto
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Kenji Yokoyama
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Ken Sadahira
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Tomoki Ueda
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Yuiko Tsukada
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Shinichiro Okamoto
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Kenji Yokoyama.

About this article

Cite this article

Hashimoto, N., Yokoyama, K., Sadahira, K. et al. Itraconazole may increase the risk of early-onset bortezomib-induced peripheral neuropathy. Int J Hematol 96, 758–763 (2012). https://doi.org/10.1007/s12185-012-1224-5

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s12185-012-1224-5

Keywords

Search

Navigation